Drug hybridization strategies: Before or after lead identification?

Expert Opinion on Drug Discovery

Volumn 4, Issue 6, 2009, Pages 605-609

  Fraga, Carlos Alberto Manssour ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Drug design; Dual ligands; Molecular hybridization; Multi targeted drugs; Symbiotic approach

Indexed keywords

ANTIASTHMATIC AGENT; ANTIRHEUMATIC AGENT; IMIDAZO[1,2 A]PYRIDINE DERIVATIVE; LASSBIO 1135; LASSBIO 341; LASSBIO 468; LIGAND; OZAGREL; PHOSPHODIESTERASE IV INHIBITOR; RIDOGREL; TEPOXALIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; LIGAND BINDING; MOLECULAR HYBRIDIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 67649094515     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440902956636     Document Type: Review

References (20)

1. Lombardino JG, Lowe-III JA. A guide to drug discovery: the role of the medicinal chemist in drug discovery - then and now. Nat Rev Drug Discov 2004;3:853-862
2. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78-84 (Pubitemid 40109592)
3. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49 (Pubitemid 40089827)
4. Barreiro EJ. Strategy of molecular simplification in rational drug design: the discovery of a new cardioactive agent. Quim Nova 2002;25:1172-1180
5. Viegas-Junior C, Danuello A, Bolzani VS, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:18-29-1852 (Pubitemid 47163402)
6. Lazar C, Kluczyk A, Kiyota T, et al. Drug evolution concept in drug design: 1. Hybridization method. J Med Chem 2004;47:6973-6982
7. Terasaka T, Kinoshita T, Kuno M, et al. A highly potent non-nucleoside adenosine deaminase inhibitor. Efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004;126:34-35 (Pubitemid 38090326)
8. Jones LH, Allan G, Barba O, et al. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J Med Chem 2009;52:1219-1223
9. Csemely P, Ágoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178-182 (Pubitemid 40432652)
10. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-690
11. Wermuth CG. Multitargeted drugs: the end of the "one-target-one- disease" philosophy? Drug Discov Today 2004;9:826-827
12. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-651 (Pubitemid 38981718)
13. Barreiro EJ, Fraga CAM. New insights for multifactorial disease therapy: the challenge of the symbiotic drugs. Curr Drug Ther 2008;3:1-13 (Pubitemid 351223158)
14. Cardoso CR, Brito FCF, daSilva KCM, et al. Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorg Med Chem Lett 2002;12:9-12
15. Lima LM, Castro P, Machado AL, et al. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem 2002;10:3067-3073 (Pubitemid 34761888)
16. Lacerda RB, Lima CKF, daSilva KCM, et al. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem 2009;17:84-174
17. daSilva GMS, Lima LM, Fraga CAM, et al. The molecular basis for coxib inhibition of p38α MAP kinase. Bioorg Med Chem Lett 2005;15:3506-3509
18. Espinoza-Fonseca LM. Knowledgebase for addiction-related genes: is it possible an extrapolation to rational multi-target drug design? Bioorg Med Chem 2008;16:9346-9348
19. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-6543 (Pubitemid 41504710)
20. Man-Chin C, Ferreira EI. The latentiation process in drug design. Quim Nova 1999;22:75-84